BioCentury
ARTICLE | Clinical News

Immunitin: Phase II

June 30, 2003 7:00 AM UTC

Results from 25 evaluable patients in a South African Phase II trial showed that those treated with HE2000 had significantly fewer opportunistic infections compared to placebo after 13 months of treat...